Free Trial

Stevanato Group (NYSE:STVN) Upgraded at Stephens

Stevanato Group logo with Medical background

Stevanato Group (NYSE:STVN - Get Free Report) was upgraded by research analysts at Stephens to a "strong-buy" rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other equities research analysts have also weighed in on STVN. UBS Group lowered their price target on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a report on Friday, March 7th. William Blair reaffirmed an "outperform" rating on shares of Stevanato Group in a research report on Friday, March 7th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of €25.70 ($29.20).

View Our Latest Stock Report on STVN

Stevanato Group Stock Performance

NYSE:STVN opened at €21.65 ($24.60) on Monday. The firm's fifty day simple moving average is €20.64 and its 200 day simple moving average is €20.70. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. Stevanato Group has a twelve month low of €16.56 ($18.82) and a twelve month high of €28.77 ($32.69). The firm has a market capitalization of $6.56 billion, a price-to-earnings ratio of 46.06, a PEG ratio of 7.18 and a beta of 0.52.

Stevanato Group (NYSE:STVN - Get Free Report) last posted its earnings results on Thursday, March 6th. The company reported €0.20 ($0.23) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of €0.20 ($0.23). The business had revenue of €352.68 million during the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. As a group, equities research analysts expect that Stevanato Group will post 0.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stevanato Group

Several large investors have recently modified their holdings of the stock. AMI Asset Management Corp acquired a new stake in Stevanato Group during the fourth quarter valued at approximately $1,089,000. SG Americas Securities LLC raised its position in shares of Stevanato Group by 18.2% during the 4th quarter. SG Americas Securities LLC now owns 15,546 shares of the company's stock valued at $339,000 after acquiring an additional 2,389 shares in the last quarter. Jennison Associates LLC bought a new position in Stevanato Group during the fourth quarter worth $20,239,000. Conestoga Capital Advisors LLC boosted its holdings in Stevanato Group by 5.3% in the fourth quarter. Conestoga Capital Advisors LLC now owns 8,082,996 shares of the company's stock worth $176,128,000 after purchasing an additional 407,086 shares during the period. Finally, Truist Financial Corp increased its stake in Stevanato Group by 4.2% during the fourth quarter. Truist Financial Corp now owns 26,900 shares of the company's stock valued at $586,000 after purchasing an additional 1,073 shares during the last quarter.

Stevanato Group Company Profile

(Get Free Report)

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.

See Also

Analyst Recommendations for Stevanato Group (NYSE:STVN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stevanato Group Right Now?

Before you consider Stevanato Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.

While Stevanato Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Markets in Rally Mode: Will Earnings Keep It Going?
3 Tech Stocks to Buy Now—And 3 You’ll Regret Keeping
After Stellar Earnings, Is TSMC the Next Chip Leader?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines